Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhatt

Showing results (201-210 of 203) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 203 results.
Nature Chemical Biology|April 29, 2025
Facile generation of drug-like conformational antibodies specific for amyloid fibrilsAlec A Desai, Jennifer M Zupancic, Hanna Trzeciakiewicz, et al.
Malaria Journal|May 7, 2026
Protocol for a multicentric open-label randomized controlled trial comparing low-dose (0.25 mg/kg) and standard-dose (0.75 mg/kg) primaquine for gametocytocidal efficacy and safety in Plasmodium falciparum malariaPayal Gulati, Richa Singhal, Apoorv Gupta, et al.
South Asian Journal of Cancer|March 24, 2025
Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)Purvish M Parikh, Ghanashyam Biswas, Nilesh Ashok Dhamne, et al.
Pageof 21

Showing results (201-210 of 203) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 203 results.
Nature Chemical Biology|April 29, 2025
Facile generation of drug-like conformational antibodies specific for amyloid fibrilsAlec A Desai, Jennifer M Zupancic, Hanna Trzeciakiewicz, et al.
Malaria Journal|May 7, 2026
Protocol for a multicentric open-label randomized controlled trial comparing low-dose (0.25 mg/kg) and standard-dose (0.75 mg/kg) primaquine for gametocytocidal efficacy and safety in Plasmodium falciparum malariaPayal Gulati, Richa Singhal, Apoorv Gupta, et al.
South Asian Journal of Cancer|March 24, 2025
Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)Purvish M Parikh, Ghanashyam Biswas, Nilesh Ashok Dhamne, et al.
Pageof 21